- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/4192 - 1,2,3-Triazoles
Patent holdings for IPC class A61K 31/4192
Total number of patents in this class: 1917
10-year publication summary
|
116
|
130
|
137
|
130
|
122
|
140
|
122
|
139
|
142
|
100
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4757 |
30 |
| Achillion Pharmaceuticals, Inc. | 155 |
24 |
| Merck Sharp & Dohme LLC | 3734 |
24 |
| The Regents of the University of California | 20868 |
21 |
| Board of Regents, The University of Texas System | 6161 |
21 |
| F. Hoffmann-La Roche AG | 7796 |
19 |
| GW Research Limited | 147 |
19 |
| Idorsia Pharmaceuticals Ltd. | 333 |
19 |
| Novartis AG | 10174 |
18 |
| Gilead Sciences, Inc. | 2243 |
17 |
| Hoffmann-La Roche Inc. | 3832 |
16 |
| Merck Patent GmbH | 5742 |
16 |
| Theravance Biopharma R&D IP, LLC | 360 |
15 |
| Boehringer Ingelheim International GmbH | 4488 |
14 |
| Emory University | 1724 |
13 |
| Eonhf, Inc. | 45 |
13 |
| Merck Sharp & Dohme Corp. | 2183 |
12 |
| The Scripps Research Institute | 1345 |
12 |
| University of Tennessee Research Foundation | 766 |
12 |
| Vertex Pharmaceuticals Incorporated | 1576 |
11 |
| Other owners | 1571 |